跳至主要内容
临床试验/NCT05296122
NCT05296122已完成不适用

Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesion Using the Tranberg® Thermal Therapy System and Tranberg® Thermoguide Workstation

Clinical Laserthermia Systems AB2 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2022年5月12日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
14
试验地点
2
主要终点
Device and procedure related adverse events

研究概览

简要总结

This will be an open-label, pilot, exploratory, single centre clinical investigation. This is an early feasibility single arm study. No formal hypothesis is proposed. A total of up to 15 evaluable subjects receiving a non-radical ablation is planned.

The safety and feasibility outcomes will be measured directly post-treatment, 48h and 3 months post-treatment.

A minimal invasive neurosurgical approach with a Magnetic Resonance Imaging (MRI)-based stereotactic guidance system will be utilized for the planning, navigation, intracranial access, placement and confirmation of the Laser applicator prior to ablation.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Device Feasibility
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Lesions eligible for Laser Interstitial ThermoTherapy (LITT), target tumor ≤10cc in volume
  • Age ≥ 18 and < 80 years
  • Ability to undergo contrast-enhanced Computed Tomography (CT), Positron Emission Tomography (PET)-CT and contrast-enhanced MRI.
  • Women of childbearing potential must have a negative pregnancy test.
  • Eastern Cooperative Oncology Group (ECOG) performance status of ≤2
  • Primary glioblastoma/astrocytoma WHO grade IV confirmed by 1)Magnetic Resonance Imaging according to RANO citera and 2)Frozen section biosy diagnosis, and considered not suitable for open surgery or other primary treatment, or Recurrent glioblastoma/astrocytoma WHO grade IV confirmed by Magnetic Resonance Imaging according to RANO criteria.
  • ≥3 months since last radiotherapy of the brain
  • Supratentorial tumor localization with or without prior surgery for recurrence.
  • Life expectancy of ≥3 months
  • The subject reports having understood and has signed the Informed Consent Form (ICF) and is willing to comply with all investigation visits and assessments.
  • Anticipated compliance with treatment and follow-up

排除标准

  • Subject contraindicated for MRI, including subjects who may have contraindications due to implanted medical devices
  • Subject evaluated not to be fit for surgery due to liver/kidney/other organ dysfunction verified by laboratory tests
  • Identified intratumoral cystic or haemorrhagic transformation in target tumor
  • Known bleeding disorder
  • ECOG performance status of >2
  • Previous (within 30 days prior to enrollment / randomization) and concurrent treatment during the treatment phase with other investigational drug/s or device/s
  • Pregnancy or breastfeeding
  • The subject has a cognitive incapacity or language barrier precluding adequate understanding or cooperation
  • The subject is considered by the Investigator to be unsuitable to participate in the investigation for any other reason.
  • Any severe diseases interfering with the performance, evaluation, and outcome of the clinical evaluation

结局指标

主要结局

Device and procedure related adverse events

时间窗: From Day 1 throughout the study until 3 months

The number and severity of adverse events related to the TRANBERG® Laser applicator when used in MR-guided laser thermal ablation of brain lesions

次要结局

  • Device and procedure related adverse events(From Day 1 throughout the study until 3 months)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

相关资讯